Skip to main content
Jose Figueroa, MD, Oncology, Lubbock, TX

JoseAFigueroaMD

Oncology Lubbock, TX

Breast Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Thoracic Cancer

FIGSTREAM Consultants, Founder, Kiromic Biopharma, Inc., Texas

Dr. Figueroa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Figueroa's full profile

Already have an account?

  • Office

    Medical Oncology Consultants 7503 Norfolk Avenue
    Lubbock, TX 79423
    Phone+1 806-790-8817
    Fax+1 806-606-0672

Summary

  • Dr. Jose A. Figueroa is an American Board of Internal Medicine Certified Medical Oncologist and Clinical Researcher. He received his medical degree from the University of Puerto Rico School of Medicine in 1987 and completed his sub-specialty in Medical Oncology and Translational Research at the UTHSC-San Antonio, TX in 1993. Dr. Figueroa is an expert Dr Figueroa is an expert in chemotherapy, cancer immunotherapy and clinical cancer research and specializes in the treatment of patients afflicted with solid malignancies, including breast cancer, gastrointestinal cancer, gynecologic cancer, and thoracic cancer. He is also a founding member and former Chief Medical Officer of KiromicBiopharma, Inc, a start-up biotech company focused in immune target discovery and development of targeted cancer vaccines and engineered cellular (T-cell and NK cells) therapies.

Education & Training

  • University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
    University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1990 - 1993
  • VA Caribbean Healthcare System
    VA Caribbean Healthcare SystemResidency, Internal Medicine, 1987 - 1990
  • University of Puerto Rico School of Medicine
    University of Puerto Rico School of MedicineClass of 1987
  • University of Puerto Rico, Mayaguez Campus
    University of Puerto Rico, Mayaguez CampusBSc, Biology, Magna Cum Laude, 1983

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1994 - 2025
  • NM State Medical License
    NM State Medical License 2005 - 2018
  • OK State Medical License
    OK State Medical License 1993 - 1994
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Outstanding Clerkship Medical Student Educator Texas Tech University Health Sciences Center-School of Medicine, 2014
  • Excellence in Patient Care and Satisfaction Southwest Cancer Center, 2014
  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Novel Antigens in Non-small Cell Lung Cancer: SP17, AKAP4, and PTTG1 Are Potential Immunotherapeutic Targets  
    Mirandola L, Figueroa JA, Phan T, et al., Oncotarget, 1/1/2015
  • Galectin-3 Inhibition Suppresses Drug Resistance, Motility, Invasion and Angiogenic Potential in Ovarian Cancer  
    Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M, Gynecologic Oncology
  • Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy  
    Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman R, Jenkins M, Musgrove B, Radhi S, D'Cunha N,..., Int Rev Immuno, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • SP17 as a new immunotherapy target and biomarker for triple negative breast cancer.
    Chiriva-Internati M, Mirandola L, Cobos E, dahlbeck S, Nguyen D, Figueroa JA, Rahman RL, Immunology, 1/1/2015
  • High-dose-rate brachytherapy as monotherapy for favorable-risk adenocarcinoma of the prostate delivered in a single 19 Gy fraction: Preliminary results of a prospectiv...
    Dahlbeck, Scott, Chase C. Hansen, A. Robert Kagan, Carlos Torres, Maurizio Chiriva-Internati, Everardo Cobos, Jose A. Figueroa, Diane Nguyen, Lukman Tijani, and Jaden ..., Cancer Research, 1/1/2015
  • Cancer Testes Antigens: Potential New targets for Lung Cancer.
    Leonardo Mirandola, Jehanzeb Riaz, Rashmi Verma, Saba Radhi, Teresia Pham, Amardeep Aulakh, Venu Konala, Yuefei Yu, Fred Hardwick, Lukman Aderoju Tijani, Nicholas C. D..., J Clin Oncol, 1/1/2014
  • Join now to see all

Lectures

  • SP17 as a New Immunotherapy Target and Biomarker for Triple Negative Breast Cancer 
    1/1/2015
  • Translational Research Conference: Cell Cycle Regulation 
    1/1/2014
  • Clinical Research Conference (Monthly) 
    1/1/2014
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish